H.C. Wainwright raised the firm’s price target on Insmed (INSM) to $120 from $90 and keeps a Buy rating on the shares. The firm says investors have now seen the positive Phase 2A and Phase 2B studies from Insmed for treprostinil palmitil inhalation powder in pulmonary arterial hypertension patients. The firm believes successful Phase 2 progress across endpoints in PAH development has “overwhelmingly translated positively to Phase 3 and subsequent FDA approval.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $110 from $92 at Stifel
- Insmed’s TPIP Program: Promising Phase 2 Results and Market Potential Drive Buy Rating
- United Therapeutics price target lowered to $315 from $321 at BofA
- Liquidia price target lowered to $23 from $25 at BofA
- Jefferies ups Insmed target on ‘blue sky scenario’ PAH data